Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03586869 · ClinicalTrials.gov registry record · Phase 1
QUILT-3.080: NANT Pancreatic Cancer Vaccine
A Phase 1 study, sponsored by ImmunityBio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03586869: Clinical Trial Phase 1 study, sponsored by ImmunityBio.
NCT03586869 is a Phase 1 study that was terminated before completion, run by ImmunityBio. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03586869, a Phase 1 study, was terminated before completion, sponsored by ImmunityBio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care (SoC) chemotherapy.
Primary Outcome
Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03
Interventions
- DRUG Aldoxorubicin HCl
- BIOLOGICAL ALT-803
- BIOLOGICAL ETBX-011
- BIOLOGICAL ETBX-021
- BIOLOGICAL ETBX-051
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-07-17 |
| Est. Completion | 2019-08-01 |
| Phase | Phase 1 |
Why NCT03586869 stopped before completion
NCT03586869 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Aldoxorubicin HCl is the first listed.
NCT03586869 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03586869 about?
NCT03586869 is a clinical study titled "QUILT-3.080: NANT Pancreatic Cancer Vaccine". This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care (SoC) chemotherapy.
What is the current status of trial NCT03586869?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2018-07-17. Estimated completion is 2019-08-01.
What interventions are being tested in trial NCT03586869?
The interventions under investigation include: Aldoxorubicin HCl (DRUG), ALT-803 (BIOLOGICAL), ETBX-011 (BIOLOGICAL), ETBX-021 (BIOLOGICAL), ETBX-051 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03586869?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03586869's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI